Get the Daily Brief
Latest Biotech News
JAX and NYSCF unite: nonprofit research engine launched in NYC
The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and held a launch event at NYSCF’s Manhattan facilities to mark the formation of a unified nonprofit research...
Epigenovo commercializes scFFPE‑ATAC: startup seeks funding after paper
Swedish spinout Epigenovo disclosed proof‑of‑concept for a high‑throughput single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissues — scFFPE‑ATAC —...
Parse and Codebreaker map variant effects at single‑cell scale
Parse Biosciences and Codebreaker Labs announced a collaboration to combine engineered variant libraries with Parse’s single‑cell transcriptomics to experimentally measure how genetic variants...
Galux and Boehringer ink AI protein‑design pact — purposeful molecules
South Korean AI‑driven protein discovery company Galux signed a research collaboration with Boehringer Ingelheim to evaluate AI‑enabled design of purpose‑specific protein molecules. The initial...
Patient deaths trigger partial hold: Daiichi, Merck pause global Phase III ADC
The Phase III global program testing an antibody‑drug conjugate (I‑Dxd/ifinatamab deruxtecan) has been placed on partial hold after a higher‑than‑anticipated number of fatal interstitial lung...
BioMarin buys Amicus for $4.8B: rare disease portfolio expands
BioMarin agreed to acquire Amicus Therapeutics in an all‑cash transaction valued at about $4.8 billion, adding two marketed therapies for Pompe and Fabry diseases and U.S. rights to a late‑stage...
Cytokinetics wins FDA nod: Myqorzo approved for obstructive HCM
The FDA granted approval to Cytokinetics' Myqorzo—the company’s first U.S. drug—for obstructive hypertrophic cardiomyopathy, marking a milestone after a nearly three‑decade effort. Cytokinetics...
Takeda’s TYK2 drug clears Phase 3: zasocitinib posts dual trial wins
Takeda reported that zasocitinib achieved primary and key secondary endpoints in two Phase III trials for plaque psoriasis, with more than half of patients reaching 'clear or almost clear' skin...
Lilly’s oral GLP‑1 maintains weight: orforglipron meets Phase 3 goals
Eli Lilly said orforglipron, a once‑daily oral GLP‑1 receptor agonist, met primary and key secondary endpoints in a Phase 3 maintenance trial that tested whether the pill preserves weight loss...
Moderna secures CEPI funding: H5 pandemic flu vaccine advances to Phase 3
Moderna secured up to $54.3 million from CEPI to advance its mRNA H5 pandemic influenza candidate (mRNA‑1018) into Phase 3 testing and committed to allocating 20% of production capacity for low‑...
vConTACT3 and ML scale virus taxonomy: machine learning remaps viral classification
Researchers introduced vConTACT3, a machine‑learning framework enabling scalable, hierarchical classification of viruses across eukaryotic and prokaryotic domains, and published methods in Nature...
Epigenovo commercializes single‑cell FFPE ATAC: scFFPE‑ATAC heads to market
Swedish startup Epigenovo is commercializing scFFPE‑ATAC, a high‑throughput single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissues. The Uppsala...
Parse teams with Codebreaker: single‑cell variant effect mapping
Parse Biosciences and Codebreaker Labs announced a collaboration to experimentally map how engineered genetic variants alter single‑cell transcriptomes, combining Codebreaker’s variant libraries...
Insmed’s momentum stalls: Brinsupri fails nasal inflammation study, market hit
Insmed disclosed that Brinsupri (brensocatib) failed a Phase 2b trial in chronic rhinosinusitis without nasal polyps, ending a run of positive results that had elevated the company’s valuation....
FDA approves Cytokinetics heart drug — company’s first U.S. launch
The U.S. Food and Drug Administration approved Cytokinetics’ first American medicine for obstructive hypertrophic cardiomyopathy, ending a multi‑decade effort by the muscle‑biology focused...
BioMarin to buy Amicus for $4.8B — rare‑disease portfolio expands
BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in a $4.8 billion all‑cash deal that transfers two approved rare‑disease therapies and late‑stage assets into BioMarin’s portfolio....
FDA places partial hold on Merck–Daiichi ADC trial: safety probe under way
Regulators and sponsors paused a global Phase III program testing an antibody‑drug conjugate (I‑Dxd/ifinatamab deruxtecan) after investigators recorded a higher‑than‑anticipated incidence of fatal...
Moderna lands CEPI backing: $54.3M to push H5 mRNA vaccine into Phase 3
Moderna secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its mRNA‑1018 H5 avian influenza vaccine into a Phase 3 program. CEPI’s injection of...
Takeda’s TYK2 drug clears co‑primary endpoints in two Phase 3 psoriasis trials
Takeda reported that zasocitinib met co‑primary and key secondary endpoints in two large Phase 3 studies for plaque psoriasis, delivering clear or almost clear skin for more than half of treated...
Lilly’s oral orforglipron preserves weight loss — maintenance data and expedited review
Eli Lilly disclosed Phase 3 Attain‑Maintain results showing orforglipron, a once‑daily oral GLP‑1 receptor agonist, helped patients maintain weight loss over 52 weeks after prior treatment with...